🇺🇸 FDA
Pipeline program

Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection

Phase 3 small_molecule active

Quick answer

Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection for Castration resistant prostate cancer patients metastatic to bone. is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
Castration resistant prostate cancer patients metastatic to bone.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials